Best Practice & Research Clinical Rheumatology
Volume 21, Issue 1 , Pages 43-57 , February 2007

Management of established rheumatoid arthritis with an emphasis on pharmacotherapy

References 

  1. Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis. The Journal of Rheumatology. 1999;26:717–719
  2. Hochberg MC. Adult and juvenile rheumatoid arthritis: current epidemiologic concepts. Epidemiologic Reviews. 1981;3:27–44
  3. Pincus T. Long-term outcomes in rheumatoid arthritis. British Journal of Rheumatology. 1995;34:59–73
  4. Plant MJ, Jones PW, Saklatvala J, et al. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. The Journal of Rheumatology. 1998;25:417–426
  5. Harle P, Bongartz T, Scholmerich J, et al. Predictive and potentially predictive factors in early arthritis: a multidisciplinary approach. The Journal of Rheumatology. 2005;44:426–433
  6. Visser H, le Cessie S, Vos K, et al. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis and Rheumatism. 2002;46:357–365
  7. Bykerk VP, Keystone EC. What are the goals and principles of management in the early treatment of rheumatoid arthritis?. Best Practice & Research. Clinical Rheumatology. 2005;19:147–161
  8. van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with second line anti-rheumatic drugs. A randomised controlled trial. Annals of Internal Medicine. 1996;124:699–707
  9. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines . Guidelines for the management of rheumatoid arthritis: 2002 update. Arthritis and Rheumatism. 2002;46:328–346
  10. Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study). Arthritis and Rheumatism. 2005;52:3381–3390
  11. Welsing PM, van Gestel AM, Swinkels HL, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis and Rheumatism. 2001;44:2009–2017
  12. Prevoo ML, van Gestel AM, van 't Hof MA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. British Journal of Rheumatology. 1996;35:1101–1105
  13. Drossaers-Bakker KW, de Buck M, van Zeben D, et al. Long-term course and outcome of functional capacity in rheumatoid arthritis. Arthritis and Rheumatism. 1999;42:1854–1860
  14. Guillemin F, Suurmeijer T, Krol B, et al. Functional disability in early rheumatoid arthritis: description and risk factors. The Journal of Rheumatology. 1994;21:1051–1055
  15. van Leeuwen MA, van der Heijde DMFM, van Rijswijk MH, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiological damage, physical disability, joint count, and acute phase reactants. The Journal of Rheumatology. 1994;21:425–429
  16. Welsing PM, Landewe RB, van Riel PL, et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis and Rheumatism. 2004;50:2082–2093
  17. van der Heijde DM, van Leeuwen MA, van Riel PL, van de Putte LB. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). The Journal of Rheumatology. 1995;22:1792–1796
  18. Fuchs HA, Kaye JJ, Callahan LF, et al. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. The Journal of Rheumatology. 1989;16:585–591
  19. Buckari M, Harrison B, Lunt M, et al. Time to first occurrence of erosions in inflammatory polyarthritis: results from a prospective community-based study. Arthritis and Rheumatism. 2001;60:956–961
  20. Fex E, Jonsson K, Eberhard K. Development of radiographic damage during the first 5–6 years of rheumatoid arthritis. A prospective follow-up study of a Swedish cohort. British Journal of Rheumatology. 1996;35:1106–1115
  21. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis and Rheumatism. 1998;41:1571–1582
  22. Uhlig T, Smedstad LM, Vaglum P, et al. The course of rheumatoid arthritis and predictors of psychological, physical and radiographic outcome after 5 years of follow-up. Rheumatology (Oxford, England). 2000;39:732–741
  23. Hulsmans HMJ, Jacobs JWG, van der Heijde DMFM, et al. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:1927–1940
  24. Scott DL, Pugner K, Kaarlea K. The links between joint damage and disability in rheumatoid arthritis. Rheumatology. 2000;39:122–132
  25. Molenaar ET, Voskuyl AE, Dinant HJ, et al. Progression of radiologic damage in patients with rheumatoid arthritis in clinical remission. Arthritis and Rheumatism. 2004;50:36–42
  26. Guillemin F, Gerard N, van Leeuwen M. Prognostic factors for joint destruction in rheumatoid arthritis: a prospective longitudinal study of 318 patients. The Journal of Rheumatology. 2003;30:2585–2589
  27. Scott DL. Radiological progression in established rheumatoid arthritis. The Journal of Rheumatology. 2004;31(supplement 69):55–65
  28. Kroot EJJA, De Jong BAW, van Leeuwen MA, et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism. 2000;43:1831–1835
  29. Lindqvist E, Eberhardt K, Bendtzen K, et al. Prognostic laboratory markers of joint damage in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2005;64:196–201
  30. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement. Arthritis and Rheumatism. 2005;52:1020–1030
  31. Scott DL, Smith C, Kingsley G. What are the consequences of early rheumatoid arthritis for the individual?. Best Practice & Research. Clinical Rheumatology. 2005;19:117–136
  32. Pollard LC, Choy EH, Gonzalez J, et al. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology (Oxford, England). 2006;45:885–889
  33. Gabriel SE, Crowson CS, Maradit Kremers H, et al. Survival in rheumatoid arthritis; a population-based analysis of trends over 40 years. Arthritis and Rheumatism. 2003;48:54–58
  34. Kroot EJ, van Leeuwen MA, van Rijswijk MH, et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Annals of the Rheumatic Diseases. 2000;59:954–958
  35. Callahan LF, Pincus T. Mortality in the rheumatic diseases. Arthritis Care and Research. 1995;8:229–241
  36. Boers M, Dijkmans B, Gabriel S, et al. Making an impact on mortality in rheumatoid arthritis; targeting cardiovascular comorbidity. Arthritis and Rheumatism. 2004;50:1734–1739
  37. Gabriel S, Crowson C, O'Fallon M. Comorbidity in arthritis. The Journal of Rheumatology. 1999;26:2475–2479
  38. Kroot EF, van Gestel AM, Swinkels H, et al. Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. The Journal of Rheumatology. 2001;28:1511–1517
  39. Berkanovic E, Hurwicz ML. Rheumatoid arthritis and comorbidity. The Journal of Rheumatology. 1990;17:888–892
  40. Pincus T, Brooks RH, Callahan LF. Prediction of long-term mortality in patients with rheumatoid arthritis according to simple questionnaire and joint count measures. Annals of Internal Medicine. 1994;120:26–34
  41. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis; a population-based study. Arthritis and Rheumatism. 2005;52:722–732
  42. Dechant SA, Matteson EL. Managing comorbidity risks in rheumatoid arthritis. Current Opinion in Rheumatology. 2004;16:177–179
  43. Wållberg-Jonsson S, Öhman M-L, Rantapää-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis?. Scandinavian Journal of Rheumatology. 2004;33:373–379
  44. Solomon DH, Karlson EW, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnoses with rheumatoid arthritis. Circulation. 2003;107:1303–1307
  45. Chung CP, Oeser A, Raggi P, et al. Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis and Rheumatism. 2005;52:3045–3053
  46. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis and Rheumatism. 2006;54:692–701
  47. Wolfe F, Mitchell DM, Sibley JT, et al. The mortality of rheumatoid arthritis. Arthritis and Rheumatism. 1994;37:481–494
  48. Riise T, Jacobsen BK, Gran JT, et al. Total mortality is increased in rheumatoid arthritis. A 17-year prospective study. Clinical Rheumatology. 2001;20:123–127
  49. Navarro-Cano G, del Rincón I, Pogosian S. Association of mortality with disease severity in rheumatoid arthritis, independent of comorbidity. Arthritis and Rheumatism. 2003;48:2425–2433
  50. Peltomaa R, Paimela L, Kautiainen H, Leirisalo-Repo M. Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Annals of the Rheumatic Diseases. 2002;61:889–894
  51. Rat A-C, Boissier M-C. Rheumatoid arthritis: direct and indirect costs. Joint, Bone, Spine: Revue du Rhumatisme. 2004;71:518–524
  52. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Seminars in Arthritis and Rheumatism. 2000;29:305–320
  53. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatology (Oxford, England). 2000;39:28–33
  54. Welsing PMJ, Kievit W, Laan RFJM, Severens JL. Quality of life and costs for different treatment strategies for rheumatoid arthritis. Expert Review of Pharmacoeconomics and Outcomes Research. 2005;5:395–410
  55. Verstappen SMM, Verkleij H, Bijlsma JWJ, et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Annals of the Rheumatic Diseases. 2004;63:817–824
  56. Jones G, Halbert J, Crotty M, et al. The effect of treatment on radiological progression in rheumatoid arthritis: a systematic review of randomized placebo-controlled trials. Rheumatology (Oxford, England). 2003;42:6–13
  57. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet. 1999;354:1932–1939
  58. Klareskog L, van der Heijde D, de Jage JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363:675–681
  59. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis and Rheumatism. 2004;50:1400–1411
  60. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Annals of the Rheumatic Diseases. 2004;63:1062–1068
  61. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis and Rheumatism. 2005;52:2229–2232
  62. Edwards JCW, Szczepański L, Szechiński J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. New England Journal of Medicine. 2004;350:2575–2581
  63. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents specifically tumour necrosis factor alpha (TNFalpha) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Annals of the Rheumatic Diseases. 2005;64:iv2–iv14
  64. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. The New England Journal of Medicine. 2000;343:1594–1602
  65. Finckh A, Simard JF, Duryea J, et al. The effectiveness of anti-tumour necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis. Arthritis and Rheumatism. 2006;54:54–59
  66. Bijlsma JWJ, van Everdingen AA, Huisman M, et al. Glucocorticoids in rheumatoid arthritis: effects on erosions and bone. Annals of the New York Academy of Sciences. 2002;966:82–90
  67. Choy EH, Kingsley GH, Khoshaba B, et al. A two year randomised controlled trial of intramuscular depot steroids in patients with established rheumatoid arthritis who have shown an incomplete response to disease modifying antirheumatic drugs. Annals of the Rheumatic Diseases. 2005;64:1288–1293
  68. Choy EHS, Smith C, Doré CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford, England). 2005;44:1414–1421
  69. Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. Arthritis and Rheumatism. 2002;46:347–356
  70. Korpela M, Laasonen L, Hannonen P, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs. Arthritis and Rheumatism. 2004;50:2072–2081
  71. Van Riel PLCM, Haagsma CJ, Furst DE. Pharmacotherapeutic combination strategies with disease-modifying antirheumatic drugs in established rheumatoid arthritis. Baillière's Best Practice & Research. Clinical Rheumatology. 1999;13:687–700
  72. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet. 1997;350:309–318
  73. Pincus T, Yazici Y, Sokka T, et al. Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clinical and Experimental Rheumatology. 2003;21(supplement 31):S179–S185
  74. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Annals of Internal Medicine. 1999;131:768–774
  75. Hochberg MC, Tracy JK, Hawkins-Holt M, et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Annals of the Rheumatic Diseases. 2003;62(supplement II):ii13–ii16
  76. Van Vollenhoven R, Harju A, Brannemark S, Klareskog L. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Annals of the Rheumatic Diseases. 2003;62:1195–1198
  77. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial. Annals of Internal Medicine. 2002;137:726–733
  78. Sarzi-Puttini P, D'Ingianna E, Fumagalli M, et al. An open, randomized comparison study of cyclosporine A, cyclosporine A+methotrexate and cyclosprorine A+hydroxychloroquine in the treatment of early severe rheumatoid arthritis. Rheumatology International. 2005;25:15–22
  79. Lehman AJ, Esdaile JM, Klinkhoff AV, et al. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study. Arthritis and Rheumatism. 2005;52:1360–1370
  80. Dougados M, Emery P, Lemmel EM, et al. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?. Annals of the Rheumatic Diseases. 2005;64:44–51
  81. Roj Kovich B, Hodinka L, Balint G, et al. Cyclosporine and sulphasalazine combination in treatment of early rheumatoid arthritis. Scandinavian Journal of Rheumatology. 1999;28:216–221
  82. Van den Borne BE, Landewe RB, Geoi HS, et al. Combination therapy in recent rheumatoid arthritis: a randomised double blind trial of low dose cyclosporin to patients treated with low dose chloroquine. The Journal of Rheumatology. 1998;25:1493–1498
  83. Nelissen RGHH. The impact of total joint replacement in rheumatoid arthritis. Best Practice & Research. Clinical Rheumatology. 2003;17:831–846
  84. Astin JA, Beckner W, Soeken K, et al. Psychological interventions for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis and Rheumatism. 2002;47:291–302
  85. Hawley DJ. Psycho-educational interventions in the treatment of arthritis. Baillère's Clinical Rheumatology. 1995;9:803–823
  86. Van den Ende CHM, Vliet Vlieland TPM, Munneke M, Hazes JMW. Dynamic exercise therapy in rheumatoid arthritis: a systematic review. British Journal of Rheumatology. 1998;37:677–687
  87. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis and Rheumatism. 2000;43:22–29
  88. Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. The Journal of Rheumatology. 2006;33:248–255
  89. Hyrich KL, Watson KD, Silman SJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford, England). 2006;[E-pub May 16 2006]
  90. Padyukov L, Lampa J, Heimbürger M, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. Annals of the Rheumatic Diseases. 2003;62:526–529
  91. Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fcγ receptor type IIIa polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumour necrosis factor α-blocking agents. Arthritis and Rheumatism. 2005;52:2693–2696
  92. Fransen J, Bernelot Moens H, Speyer I, van Riel PLCM. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. Annals of the Rheumatic Diseases. 2005;64:1294–1298
  93. Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet. 2004;364:263–269
  94. Fries JF. The hierarchy of outcome assessment. The Journal of Rheumatology. 1993;20:546–547
  95. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. Arthritis and Rheumatism. 1980;23:137–145
  96. Fries JF. Toward an understanding of patient outcome measurement. Arthritis and Rheumatism. 1983;26:697–704
  97. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. Arthritis and Rheumatism. 1993;36:729–740
  98. Goldsmith CH, Boers M, Bombardier C, et al. for the OMERACT Committee. Criteria for clinically important changes in outcomes: development, scoring, and evaluation of the rheumatoid arthritis patient and trial profiles. The Journal of Rheumatology. 1993;20:561–565
  99. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis and Rheumatism. 1995;38:727–735
  100. Van Gestel AM, Prevoo MLL, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arthritis and Rheumatism. 1996;39:34–40
  101. Meenan RF, Gertman PM, Mason JH. Measuring health status in arthritis. The arthritis impact measurement scales. Arthritis and Rheumatism. 1980;23:146–152
  102. Spitz PW, Fries JF. The present and future of comprehensive outcome measures for rheumatic diseases. Clinical Rheumatology. 1987;6(supplement 2):105–111
  103. Tugwell P, Bombardier C, Buchanan WW, et al. The MACTAR Patient Preference Disability Questionnaire – an individualized functional priority approach for assessing improvement in physical disability in clinical trials in rheumatoid arthritis. The Journal of Rheumatology. 1987;14:446–451
  104. Fitzpatrick R, Newman S, Lamb R, Shipley M. A comparison of measures of health status in rheumatoid arthritis. British Journal of Rheumatology. 1989;28:201–206
  105. Østergaard M, Szkudlarek M. Imaging in rheumatoid arthritis – why MRI and ultrasonography can no longer be ignored. Scandinavian Journal of Rheumatology. 2003;32:63–73
  106. Sharp JT, Lidsky MD, Collins LC, Moreland J. Method of scoring the progression of radiologic changes in rheumatoid arthritis. Arthritis and Rheumatism. 1971;14:706–720
  107. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by reference films. Acta Radiologica: Diagnosis. 1977;18:481–491
  108. van der Heijde D, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulfasalazine on progression of joint damage in rheumatoid arthritis. Lancet. 1989;1:1036–1038
  109. Rau R, Herborn G. A modified version of Larsen's scoring method to assess radiologic changes in rheumatoid arthritis. The Journal of Rheumatology. 1995;22:1976–1982
  110. van der Heijde D, Dankert T, Nieman F, et al. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. Rheumatology (Oxford, England). 1999;38:941–947
  111. Guillemin F, Billot L, Boini S, et al. Reproducibility and sensitivity to change of 5 methods for scoring hand radiographic damage in patients with rheumatoid arthritis. The Journal of Rheumatology. 2005;32:778–786
  112. van der Heijde DMFM, van 't Hof MA, van Riel PLCM, van de Putte LBA. Validity of single variables and indices to measure disease activity in rheumatoid arthritis. The Journal of Rheumatology. 1993;20:538–541
  113. Prevoo ML, van 't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism. 1995;38:44–48
  114. Smolen JS, Breedveld FC, Schiff MH, et al. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford, England). 2003;42:244–257
  115. Stucki G, Liang MH, Stucki S, et al. Self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. Arthritis and Rheumatism. 1995;38:795–798
  116. Rau R, Wassenberg S, Herborn G, et al. A new method of scoring radiographic change in rheumatoid arthritis. The Journal of Rheumatology. 1998;25:2094–2106

PII: S1521-6942(06)00121-5

doi: 10.1016/j.berh.2006.09.002

Best Practice & Research Clinical Rheumatology
Volume 21, Issue 1 , Pages 43-57 , February 2007

Article Tools